Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

., S Hall A2
  • Poster session: Lymphoma and Plasma Cell Disorders
  • Abstract #8135, poster board 37E

    • Solid Tumors & Multiple Myeloma

    Updated Results of a Phase 1b/2 Study of Carfilzomib in Patients with Relapsed Malignancies

    • Dr. Peter Lee, Tower Cancer Research Foundation
    • Saturday, June 5, 2010, 8:00 a.m. - 12:00 p.m., S Hall A2
    • Poster session: Lymphoma and Plasma Cell Disorders
    • Abstract #8147, poster board 39A

    About the Carfilzomib Development Program

    Carfilzomib is a selective, next generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma.

    In addition, the company intends to initiate a large, randomized international Phase 3 clinical trial, known as the 009 trial, this year to study the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMEA) on the design and planned analysis of the 009 trial. A second Phase 3 clinical trial, the 011 trial, of carfilzomib in relapsed and refractory myeloma is planned in Europe. Carfilzomib is also being evaluated in advanced solid tumors.

    About Multiple Myeloma

    Multiple myeloma (MM) is the second most common hematologic cancer and results from an abnormality of plasma cells, usually
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... such as primary biliary cirrhosis, today announced that ... Executive Officer, will present at the Deutsche Bank Securities ... on Wednesday, May 29, 2013 at 4:10 ...
    (Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
    (Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
    Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
    ... ... Study, Pharmacokinetic Study Demonstrates Lack of Systemic Exposure of XIAFLEX, ... Conference call scheduled for today, June 3, at 8:45 a.m. Eastern Time, ... positive top-line,efficacy and safety results from the CORD I and CORD II phase ...
    ... 2 Alliance,Pharmaceutical Corp. (OTC Bulletin Board: ALLP) announced ... the two proposals put to the,shareholders at its Annual ... first proposal related to the re-election of each of ... additional term of one year or,until their successors are ...
    Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting 2
    (Date:5/23/2013)... The sodium theory has ... B. Katz in the early 1950s, after their experiments ... sodium and potassium ions in nerve functions . ... techniques have known amazing developments. In The Sodium Theory ... an account of the latest developments in the field ...
    (Date:5/23/2013)... (PRWEB) May 23, 2013 Voyance, ... and perception management tools, and ASCA, the industry’s ... the new ASCA Benchmarking Program. Voyance ... technology and national benchmarking experience to support ASCA’s ... comprehensive, state-of-the-art benchmarking tool. , “Voyance is both ...
    (Date:5/23/2013)... Park, FL (PRWEB) May 23, 2013 ... Day Belly Blast Diet to determine what makes this ... , The published review highlights three main components of ... rate; achieving a positive mindset and the personal motivation ... calorie intake every 7 days to keep the metabolism ...
    (Date:5/23/2013)... eat at fast-food restaurants are consuming significantly more calories ... offenders, a new study found. "Teens underestimate the ... as 34 percent, parents of school-age children by as ... as 20 percent," study lead researcher, Dr. Jason Block, ... Johnson Foundation, which helped fund the study. ...
    (Date:5/23/2013)... Susquehanna Health is now ... babysitting training course for adolescents age 11 and up. ... pediatrician Dr. Patricia Keener after a colleague’s toddler choked ... sitter who didn’t know how to provide first aid. ... a medical basis that aims to reduce the number ...
    Breaking Medicine News(10 mins):Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3
    ... in Central Mexico who used a vented stove instead of ... par with a pack-a-day smoker kicking the habit, according to ... first year of data in an ongoing project examining the ... open fires, was reported in the October 1 issue of ...
    ... NEW YORK, Sept. 22 Preet Bharara, the U.S. Attorney ... Dowd, formerly the senior manager of human resources of Hitachi America ... 57 months in prison for defrauding the Hitachi America Group Health ... sentence was imposed by U.S. District Judge Colleen McMahon. Dowd pleaded ...
    ... ... bioidentical hormone replacement therapy and nutritional supplements in battle against the deadly disease ... Jacksonville, Fla. (Vocus) ... than five million people in the United States and 35 million people worldwide are ...
    ... , NEW YORK, Sept. 22 Assurant, Inc. ("Assurant") (NYSE: ... products and services, will release 2009 third quarter financial results on Wednesday, ... available on Assurant,s Web site at www.assurant.com . , ... conference call at 9:00 a.m. ET on Thursday, Oct. 29, 2009 with ...
    ... , , , , ... provide affordable health insurance for all, , , ... public or private , , Sixty-three percent favor ... A nationwide survey commissioned by the United States Conference of Catholic Bishops ...
    ... , , SCHAUMBURG, Ill., Sept. 22 ... Peter Beilenson, MD, MPH, announced they are introducing a regulation to ... of indoor tanning devices for all residents under the age of ... its kind in the nation. , , "The ...
    Cached Medicine News:Health News:New stove dramatically improves lung health in Mexican women 2Health News:New stove dramatically improves lung health in Mexican women 3Health News:Former Corporate Benefits Manager Sentenced to 57 Months in Prison for Defrauding Health Care Plan of More Than $6 Million Dollars 2Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 2Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 3Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 4Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 5Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:New Survey: Most Americans Want Health Care Reform, Oppose Abortion Coverage, Support Conscience Protection Laws 2Health News:American Academy of Dermatology Association Commends Howard County for Proposing the Most Restrictive Indoor Tanning Regulation in the Country 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: